PIGL is highly expressed in docetaxel-resistant PCa and associated with poor prognosis.
HUWE1 is identified as an E3 ubiquitin ligase that regulates PIGL protein levels.
Knockdown of HUWE1 promotes docetaxel resistance in PCa cells.
PIGL's role in PCa progression and drug resistance is emphasized.
The study provides insights into mechanisms of chemotherapy resistance in PCa, highlighting potential therapeutic targets.
Guideline-Based Recommendations
Diagnosis
Assess PIGL expression levels in prostate cancer patients.
Management
Consider targeting PIGL and HUWE1 pathways in treatment strategies for docetaxel-resistant PCa.
Monitoring & Follow-up
Monitor PIGL and HUWE1 expression as potential biomarkers for treatment response and adjust treatment plans accordingly.
Risks
High PIGL expression may indicate increased risk of docetaxel resistance.
Patient & Prescribing Data
Patients with metastatic hormone-sensitive prostate cancer (mHSPC) and castration-resistant prostate cancer (CRPC), focusing on docetaxel resistance mechanisms.
Docetaxel is a key treatment but resistance is a significant challenge, particularly in advanced stages.
Clinical Best Practices
Evaluate the role of PIGL in individual patient treatment plans, especially for those with docetaxel resistance.
Incorporate molecular profiling in managing advanced PCa, including PIGL and HUWE1 assessments.
